Issue 4, 2019

Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents

Abstract

A series of tryptamine salicylic acid derivatives were synthesized and their antiproliferative activity against MGC-803, MCF-7, HepG2, A549 and HeLa cell lines was evaluated. The structure–activity relationship (SAR) study revealed that different substitutions of the C5 and C3′–C5′ positions have certain effects on the anti-proliferation activity. The growth assay revealed that N-[2-(5-bromo-1H-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide (E20) showed the most potent and broad-spectrum anticancer inhibition of all the cell lines evaluated, and was only more potent than 5-Fu for the gastric cancer cell line. Preliminary studies indicated that compound E20 could inhibit colony formation and migration of MGC-803 cells. The flow cytometry (FCM) results showed that compound E20 arrested the cell cycle in the G2/M phase and induced apoptosis of MGC-803 cells in a concentration-dependent manner. In addition, the western blot results showed that E20 can down-regulate the expression of hexokinase 2. Our studies suggest that the framework of N-[2-(5-bromo-1H-indol-3-yl)-ethyl]-2-hydroxy-3-methyl-benzamide may be consider as a new type of chemical for designing effective anti-cancer drugs targeting gastric cancer cells.

Graphical abstract: Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents

Supplementary files

Article information

Article type
Research Article
Submitted
27 Sep 2018
Accepted
05 Jan 2019
First published
11 Jan 2019

Med. Chem. Commun., 2019,10, 573-583

Design, synthesis and biological evaluation of tryptamine salicylic acid derivatives as potential antitumor agents

R. Xiong, D. He, X. Deng, J. Liu, X. Lei, Z. Xie, X. Cao, Y. Chen, J. Peng and G. Tang, Med. Chem. Commun., 2019, 10, 573 DOI: 10.1039/C8MD00484F

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements